Abstract: Biguanide compounds of formula where R1 comprises a cubanyl-substituted alkyl and R2 comprises a substituted or unsubstituted alkyl, and their use in the treatment of cancers and viral infections are described.

Abstract: Compositions discussed herein are useful for treating a patient infected with a coronavirus, notably SARS-CoV-2 or COVID-19. The compositions to be administered to an infected patient utilize inhibitors of SARS-CoV-2 papain-like protease (PLpro). Several of these inhibitors include available hepatitis C virus (HCV) drugs that are already FDA-approved. These PLpro inhibitors have been found to be strongly synergistic with inhibitors of SARS-CoV-2 polymerases, such as RNA-dependent RNA polymerase (RdRp). One such polymerase inhibitor, remdesivir, is already in use as an anti-viral treatment of patients with COVID-19. The PLpro inhibitors, including repurposed HCV drugs such as grazoprevir, vaniprevir, and paritaprevir, increase remdesivir's ability to suppress coronavirus replication antiviral activity as much as 10-fold.

Abstract: Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composition thereof to a subject (e.g., a human subject). Also provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108110 or a composition thereof to a subject (e.g., a human subject). In addition, provided herein are methods for treating a virus (e.g., an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108600 or a composition thereof to a subject (e.g., a human subject).

Abstract: Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering Rigosertib or a composition thereof to a subject (e.g., a human subject).